MeiraGTx Holdings PLC (MGTX)vsBeiGene, Ltd. (ONC)
MGTX
MeiraGTx Holdings PLC
$12.79
-0.47%
HEALTHCARE · Cap: $1.33B
ONC
BeiGene, Ltd.
$346.51
+1.38%
HEALTHCARE · Cap: $40.53B
Smart Verdict
WallStSmart Research — data-driven comparison
BeiGene, Ltd. generates 1442% more annual revenue ($6.13B vs $397.50M). MGTX leads profitability with a 19.9% profit margin vs 10.7%. MGTX trades at a lower P/E of 16.0x. ONC earns a higher WallStSmart Score of 64/100 (C+).
MGTX
Buy61
out of 100
Grade: C+
ONC
Buy64
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for MGTX.
Margin of Safety
+80.1%
Fair Value
$1767.21
Current Price
$346.51
$1420.70 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Strong operational efficiency at 76.0%
Revenue surging 8609.0% year-over-year
Attractively priced relative to earnings
Earnings expanding 166.7% YoY
Conservative balance sheet, low leverage
Growing faster than its price suggests
Revenue surging 29.6% year-over-year
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -368.2% — below average capital efficiency
Negative free cash flow — burning cash
Premium valuation, high expectations priced in
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : MGTX
The strongest argument for MGTX centers on Operating Margin, Revenue Growth, P/E Ratio. Profitability is solid with margins at 19.9% and operating margin at 76.0%. Revenue growth of 8609.0% demonstrates continued momentum.
Bull Case : ONC
The strongest argument for ONC centers on EPS Growth, Debt/Equity, PEG Ratio. Revenue growth of 29.6% demonstrates continued momentum. PEG of 0.77 suggests the stock is reasonably priced for its growth.
Bear Case : MGTX
The primary concerns for MGTX are EPS Growth, Market Cap, Return on Equity.
Bear Case : ONC
The primary concerns for ONC are P/E Ratio, Altman Z-Score. A P/E of 64.1x leaves little room for execution misses.
Key Dynamics to Monitor
MGTX carries more volatility with a beta of 1.27 — expect wider price swings.
MGTX is growing revenue faster at 8609.0% — sustainability is the question.
ONC generates stronger free cash flow (596M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ONC scores higher overall (64/100 vs 61/100) and 29.6% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
MeiraGTx Holdings PLC
HEALTHCARE · BIOTECHNOLOGY · USA
MeiraGTx Holdings plc, a clinical-stage gene therapy company, focused on developing treatments for patients living with serious illnesses. The company is headquartered in New York, New York.
BeiGene, Ltd.
HEALTHCARE · BIOTECHNOLOGY · USA
BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company is headquartered in Camana Bay, the Cayman Islands.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?